ABOS — Acumen Pharmaceuticals, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1576885 ·
Last close
$2.15
Market Cap
$155.29M
52W High
$2.83
52W Low
$2.08
ADV30
584,993
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -21,149,000 | -20,737,000 | 133,629,000 | 51,796,000 | 46,153,000 |
| Dec 2025 | 0 | — | -25,199,000 | -25,138,000 | 122,833,000 | 53,989,000 | 52,403,000 |
| Sep 2025 | 0 | — | -26,513,000 | -26,451,000 | 142,221,000 | 46,832,000 | 49,048,000 |
| Jun 2025 | 0 | — | -41,750,000 | -40,950,000 | 171,897,000 | 36,810,000 | 54,820,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-105,545,000
Investing CF
$91,437,000
Financing CF
$35,744,000
CapEx
$-88,000
Dividends Paid
—
Buybacks
$-149,000
EPS Diluted TTM
$-1.93
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-467,199,000
Inventory
—
Receivables
$772,000
ST Investments
$76,602,000
EBIT TTM
$-109,006,000
Pretax Income TTM
$-113,276,000
Interest Exp TTM
$4,270,000
Analysts
5
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -123,832,000 | -121,335,000 | 122,833,000 | 52,403,000 | — | -115,538,000 |
| Dec 2024 | 0 | -114,017,000 | -102,329,000 | 238,992,000 | 57,176,000 | — | -86,215,000 |
| Dec 2023 | 0 | -61,138,000 | -52,371,000 | 310,125,000 | 43,152,000 | — | -43,064,000 |
| Dec 2022 | 0 | -45,237,000 | -42,856,000 | 196,587,000 | 7,812,000 | — | -35,153,000 |
TTM Snapshot
Revenues TTM
$6,628,000
NetIncome TTM
$-53,432,000
OpCashFlow TTM
$0
Assets (Latest)
$238,992,000
Forward EPS
$-1.51
Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)
max pain strike: $2.50 · spot: $2.15 · call volume: 19 · put volume: 2
Expected Move to 2027-01-15:
±$1.92
(89.07%) —
implied range
$0.24 –
$4.07
· ATM straddle on $2.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IPHYF | Innate Pharma SA | $154.94M | $1.65 | — |
| IVVD | Invivyd, Inc. | $157.61M | $0.54 | — |
| TNYA | Tenaya Therapeutics, Inc. | $160.58M | $0.74 | — |
| MOLN | MOLECULAR PARTNERS AG | $147.42M | $3.93 | — |
| ENTX | Entera Bio Ltd. | $147.38M | $2.99 | — |
News headlines (Yahoo Finance, 1h cache)
VERAXA Biotech Shows Regulatory Progress on Cancer Therapy Platform
2026-07-20 16:15 · Yahoo
Slate Medicines Appoints Mark W. Hahn to Board of Directors
2026-07-16 16:18 · Yahoo
All You Need to Know About Acumen Pharmaceuticals (ABOS) Rating Upgrade to Buy
2026-07-15 16:00 · Yahoo
Are Medical Stocks Lagging Acumen Pharmaceuticals (ABOS) This Year?
2026-07-15 13:40 · Yahoo
Acumen Pharmaceuticals Highlights Enhanced Brain Delivery™ (EBD™) Program Data and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 2026
2026-07-15 11:30 · Yahoo
Acumen Pharmaceuticals and Unlearn Collaborate to Explore Analyses of Alzheimer's Disease Clinical Programs
2026-07-09 10:00 · Yahoo
Acumen Pharmaceuticals to Present Data on Enhanced Brain Delivery™ (EBD™) Technology and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 2026
2026-07-07 11:30 · Yahoo
Acumen Nominates 2 Therapies to Treat Alzheimer’s Disease
2026-06-16 22:18 · Yahoo
Acumen Pharmaceuticals Announces Nomination of Two Enhanced Brain Delivery™ (EBD™) Development Candidates for the Treatment of Alzheimer’s Disease
2026-06-16 11:30 · Yahoo
Acumen Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary
2026-05-13 12:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.